Literature DB >> 27030389

Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.

Konstantinos Georgiou1, Longyun Chen2, Mattias Berglund3, Weicheng Ren1, Noel F C C de Miranda4, Susana Lisboa5, Marco Fangazio6, Shida Zhu7, Yong Hou7, Kui Wu7, Wenfeng Fang8, Xianhuo Wang9, Bin Meng9, Li Zhang8, Yixin Zeng8, Govind Bhagat10, Magnus Nordenskjöld11, Christer Sundström12, Gunilla Enblad12, Riccardo Dalla-Favera6, Huilai Zhang9, Manuel R Teixeira5, Laura Pasqualucci6, Roujun Peng8, Qiang Pan-Hammarström1.   

Abstract

Diffuse large B-cell lymphoma (DLBCL) is one of the most common and aggressive types of B-cell lymphoma. Deregulation of proto-oncogene expression after a translocation, most notably to the immunoglobulin heavy-chain locus (IGH), is one of the hallmarks of DLBCL. Using whole-genome sequencing analysis, we have identified the PD-L1/PD-L2 locus as a recurrent translocation partner for IGH in DLBCL. PIM1 and TP63 were also identified as novel translocation partners for PD-L1/PD-L2 Fluorescence in situ hybridization was furthermore used to rapidly screen an expanded DLBCL cohort. Collectively, a subset of samples was found to be affected by gains (12%), amplifications (3%), and translocations (4%) of the PD-L1/PD-L2 locus. RNA sequencing data coupled with immunohistochemistry revealed that these cytogenetic alterations correlated with increased expression of PD-L1 but not of PD-L2 Moreover, cytogenetic alterations affecting the PD-L1/PD-L2 locus were more frequently observed in the non-germinal center B cell-like (non-GCB) subtype of DLBCL. These findings demonstrate the genetic basis of PD-L1 overexpression in DLBCL and suggest that treatments targeting the PD-1-PD-L1/PD-L2 axis might benefit DLBCL patients, especially those belonging to the more aggressive non-GCB subtype.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27030389     DOI: 10.1182/blood-2015-12-686550

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  71 in total

1.  High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Sehui Kim; Soo Jeong Nam; Changhee Park; Dohee Kwon; Jeemin Yim; Seung Geun Song; Chan-Young Ock; Young A Kim; Sung Hye Park; Tae Min Kim; Yoon Kyung Jeon
Journal:  Oncoimmunology       Date:  2019-06-10       Impact factor: 8.110

Review 2.  Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers.

Authors:  Siba El Hussein; Kenna R M Shaw; Francisco Vega
Journal:  Mod Pathol       Date:  2020-07-03       Impact factor: 7.842

3.  PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.

Authors:  V Atsaves; N Tsesmetzis; D Chioureas; L Kis; V Leventaki; E Drakos; T Panaretakis; D Grander; L J Medeiros; K H Young; G Z Rassidakis
Journal:  Leukemia       Date:  2017-03-27       Impact factor: 11.528

Review 4.  Targeting the programmed death-1 pathway in lymphoid neoplasms.

Authors:  Chi Young Ok; Ken H Young
Journal:  Cancer Treat Rev       Date:  2017-02-11       Impact factor: 12.111

5.  PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.

Authors:  Marién Pascual; María Mena-Varas; Eloy Francisco Robles; Maria-Jose Garcia-Barchino; Carlos Panizo; Sandra Hervas-Stubbs; Diego Alignani; Ainara Sagardoy; Jose Ignacio Martinez-Ferrandis; Karen L Bunting; Stephen Meier; Xavier Sagaert; Davide Bagnara; Elizabeth Guruceaga; Oscar Blanco; Jon Celay; Alvaro Martínez-Baztan; Noelia Casares; Juan José Lasarte; Thomas MacCarthy; Ari Melnick; Jose Angel Martinez-Climent; Sergio Roa
Journal:  Blood       Date:  2019-04-11       Impact factor: 22.113

6.  Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.

Authors:  Thomas Menter; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2018-08-21       Impact factor: 4.064

7.  Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.

Authors:  Roch Houot; Philippe Gaulard; Robert Schreiber; Ira Mellman; Olivier Lambotte; Pierre G Coulie; Thierry Fest; Alan Korman; Ronald Levy; Margaret Shipp; Karin Tarte; Holbrook Kohrt; Aurélien Marabelle; Stephen Ansell; Hervé Watier; Andrea van Elsas; Arun Balakumaran; Frederick Arce Vargas; Sergio A Quezada; Gilles Salles; Daniel Olive
Journal:  Oncoimmunology       Date:  2016-05-19       Impact factor: 8.110

Review 8.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

9.  Multiparametric immune profiling in HPV- oral squamous cell cancer.

Authors:  Zipei Feng; Daniel Bethmann; Matthias Kappler; Carmen Ballesteros-Merino; Alexander Eckert; R Bryan Bell; Allen Cheng; Tuan Bui; Rom Leidner; Walter J Urba; Kent Johnson; Clifford Hoyt; Carlo B Bifulco; Juergen Bukur; Claudia Wickenhauser; Barbara Seliger; Bernard A Fox
Journal:  JCI Insight       Date:  2017-07-20

10.  Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.

Authors:  Weicheng Ren; Xiaofei Ye; Hong Su; Wei Li; Dongbing Liu; Mohammad Pirmoradian; Xianhuo Wang; Bo Zhang; Qiang Zhang; Longyun Chen; Man Nie; Yao Liu; Bin Meng; Huiqiang Huang; Wenqi Jiang; Yixin Zeng; Wenyu Li; Kui Wu; Yong Hou; Klas G Wiman; Zhiming Li; Huilai Zhang; Roujun Peng; Shida Zhu; Qiang Pan-Hammarström
Journal:  Blood       Date:  2018-03-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.